Prolonged viral shedding as a marker of severity in respiratory syncytial virus bronchiolitis
=============================================================================================

* Raí André Silva Watanabe
* Filipe Nishiyama
* Larissa Lyra
* Bruno Sanchez Camargo
* Luciano Kleber de Souza Luna
* Danielle Dias Conte
* Ana Helena Perosa
* Nancy Cristina Junqueira Bellei

## Abstract

**Background and Objectives** Respiratory syncytial virus (RSV) is responsible for most cases of acute viral bronchiolitis (AVB) in childhood. The association of factors such as RSV subtype, viral load, and viral coinfection with severe disease is controversial. The objective is to describe the viral load dynamics of RSV in children under 2 years with AVB, including the first viral load, peak viral load, viral decay, and any possible association with severe disease.

**Methods** 73 inpatients with AVB and confirmed RSV infection were included. Viral load was obtained through nasal swab samples daily during hospitalization and weekly after discharge until absence of detection.

**Results** 44 of the patients were male, the mean age was 5.76 months, and comorbidities were found in 15 (20.5%) of the patients. 54 (74%) of the patients had the peak viral load between the 4th and the 7th day of symptom onset. The mean duration of viral detection was 12.5 days. There was no association between the first and peak viral load with markers of severe disease. However, association was found between viral persistence exceeding 10 days and the following factors: longer hospitalization period (p=0.009), length of ventilation support (p=0.044), length of invasive mechanical ventilation (p=0.035), prolonged requirement of nutritional support (p=0.038), and a longer course of antibiotic treatment (p=0.024). Age was inversely correlated with most of the severity outcomes.

**Conclusion** Despite the lack of association between RSV viral load values and disease severity, prolonged viral shedding was associated with several adverse outcomes, which can contribute to a better understanding of RSV disease, particularly as several interventions are anticipated to become available in the coming years.

## Introduction

### Prolonged viral shedding as a marker of severity in respiratory syncytial virus bronchiolitis

Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infections and accounts for up to 80% of acute viral bronchiolitis (AVB) in childhood1,2,3. Nearly every child under two years of age is infected with the virus1, and 2-3% require hospitalization3. Recent data from the United States indicates that RSV is responsible for 9.3% of all hospitalizations among the pediatric population with an estimate burden of 1.2 billion dollars each year4. Two multi-site, international case-control studies about pneumonia etiology in children under 5 years of age were conducted in the last decade and RSV had the highest etiological fraction on the PERCH study and the second highest on the GABRIEL study5,6.

Up to 30% of AVB cases involve the detection of multiple viruses, and most cases occur within the first six months of life3,7. The risk factors for severe AVB includes lower age (specially below 3 months), prematurity, bronchopulmonary dysplasia, congenital heart disease, immunodeficiency, genetic disorders, neurological and neuromuscular disease, tobacco exposure during pregnancy, lack of breastfeeding and male sex 3,7.

Studies on RSV shedding, and clinical severity vary in methodology, age groups studied, diagnostic criteria, risk factors considered, and definitions of outcomes. Furthermore, there are variations in the timing of viral load measurements and the methods used for quantification8–13.

New interventions for managing RSV infections, such as vaccines and monoclonal antibodies, have recently been approved14. To assess their impact on the dynamics of RSV- associated AVB, it is essential to increase the understanding of RSV viral load.

The study’s objective was to characterize the dynamics of RSV viral load from the time of hospital admission to the point of viral shedding, encompassing both inpatients and outpatients. Additionally, the study intended to investigate potential associations between viral load, the RSV subgroup type, the detection of multiple viruses, and patient characteristics (such as age, gender, and comorbidities) and their impact on the severity of clinical outcomes.

## Materials and Methods

### Study Design

The study aimed to characterize the dynamics of RSV viral load, tracking it from hospital admission to the point of final viral shedding, in both inpatients and outpatients. In addition, the study sought to investigate potential associations between viral load, the RSV subgroup type, the presence of multiple viruses excluding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and patient characteristics (such as age, gender, and comorbidities) in relation to the severity of clinical outcomes.

The inclusion criteria for the study were as follows: 

1.  Hospitalized patients under 2 years of age diagnosed with acute viral bronchiolitis and not expected to be discharged within the next 24 hours.

2.  Initial assessment confirming RSV infection through reverse transcription – quantitative Polymerase Chain Reaction (RT-qPCR).

The exclusion criteria were: 

1.  Loss of follow-up before a viral load sample with no RSV detection.

2.  Patients with less than 3 collected samples.

3.  Detection of SARS-CoV-2 through RT-qPCR for a child included in the pandemic period.

### Data collection

The study utilized a convenience sample of children admitted to the hospital’s pediatric service with a clinical diagnosis of AVB. These children underwent nasopharyngeal swabs to detect RSV through RT-qPCR. The diagnosis of AVB was made by the attending pediatric physician in accordance with the guidelines of the American Academy of Pediatrics15. Nasopharyngeal swab samples were obtained by the team coordinator, trained resident physicians, or the on-duty physiotherapist for laboratory confirmation of RSV infection. Samples were collected daily during the period of the infant’s hospitalization and weekly after hospital discharge, with the collection stopping when no further RSV was detected in two consecutive samples. The day of symptom onset was defined as the first respiratory or systemic symptom of RSV infection: fever, cough, runny nose, nasal obstruction, cyanosis, apnea, respiratory distress or wheezing.

### Laboratory Methods

Each collected swab was preserved in 2.0 mL of sterile lactated Ringer’s solution and immediately transported to the virology laboratory for RSV molecular screening on the same day or stored at -80°C until investigation. The RNA of swab samples was purified using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Molecular detection of RSV was performed by a duplex quantitative RT-qPCR with TaqMan Fast Virus 1-Step Master Mix reagents (Applied Biosystems, Vilnius, Lithuania). The 20 µL of reaction volume contained 1 µM of each primer and 250 nM of the probe for RSV detection (labeled with FAM dye), aimed at the Matrix gene16, and 250 nM of each primer and probe (labeled with VIC dye) for human ribonuclease P gene detection as an internal control17. Thermocycling conditions were performed on a 7500 Real-Time PCR System (Applied Biosystems), as follow: 50°C for 2 min., 95°C for 20 sec., followed by 45 cycles of 95°C for 15 sec., and 55°C for 30 sec. (data collection). The cycle threshold of 35 was adopted as a cut-off for the human ribonuclease P and 38 for the RSV RT-qPCR.

### Viral load analysis

The viral load was measured from a standard curve generated as described elsewhere18, with an efficiency of 100.52%. The viral load was expressed in Log10 RNA copies/mL.

### RSV Subtype

The protocol of RSV subtyping was performed by Fiocruz laboratory with the sample of the highest viral load of each patient19.

### Influenza and Rhinovirus detection

An in-house real-time PCR was performed to detect Influenza A, B and rhinovirus with AgPath-ID™ One-Step RT-PCR Reagents (ThermoFischer) according to the manufacturer’s instructions. The primers and probes used for each virus detection have been published elsewhere20,21. A positive result was considered with a Ct < 40.

### Statistics

Sample size calculation was performed using G Power 3.1.9.7, based on an effect size of 0.4, power of 80%, alfa error probability of 5% using a linear regression model with 7 predictor variables. The number of patients to achieve statistical significance was 44. Data was stored in Microsoft excel 365 sheets. Statistical analysis was obtained using Jamovi (version 2.3.13) with alfa error probability of 5% and confidence interval of 95%. Graphs were built with Microsoft excel 365 and SPSS 26th edition.

Continuous variables were described as mean with standard deviation and median with interquartile range, and categorical variables as frequency rates. The 10-day cutoff for viral persistence as a categorical variable was based on the median number obtained as viral persistence.

Results were considered statistically significant when *p* value was below 0,05. Multiple linear regression was used accordingly. R2 was used to report the adequation of the model to the data and for effect size. Two models were performed, according to the equation: ![Formula][1]</img>  y = dependent variable

x = covariates

β0 = intercept

β1 = angular coefficient

ε = error

Model A: Dependent variables: (1) viral persistence; (2) peak viral load; (3) first viral load. Covariates: (1) age; (2) sex; (3) RSV subtype; (4) comorbidities; (5) rhinovirus.

Model B: Dependent variables (days of each outcome): (1) hospitalization; (2) fever; (3) use of oxygen; (4) ICU; (5) any ventilation support; (6) IMV; (7) additional nutrition support; (8) use of antibiotics. Covariates: (1) age; (2) peak viral load; (3) viral persistence over 10 days; (4) sex; (5) RSV subtype; (6) comorbidities; (7) rhinovirus.

## Results

Out of a total of 191 hospitalized patients under 2 years with AVB who were tested for RSV infection, 112 (63,9%) were positive for RSV and 73 patients were enrolled in the study. The main reasons of the exclusion for the 48 patients that had RSV detection were: (1) discharge under 24 hours; (2) hospital transfer before 3 samples collected; (3) refusal to participate. One patient had SARS-CoV-2 detection. In 2019, 40 patients were included, and in 2021, 33 patients were included. A total of 548 nasopharyngeal samples were collected from the enrolled patients, averaging 7.5 samples per patient. Out of these, 496 (90.5%) were obtained during the hospitalization period and were collected daily. Before discharge, 42 patients (57.5%) exhibited complete viral clearance.

### Characteristics of study population

The characteristics of the study population are outlined in Table 1. Comorbidities were observed in 9 patients with prematurity (12.3%), 3 patients with cardiac and neurological diseases (4.1% each), and one patient with one of the following: immunodeficiency, bronchopulmonary dysplasia, hematologic disease, renal disease, and genetic syndrome. Two of the patients had more than one comorbidity. None of the premature infants had a gestational age below 30 weeks (ranging from 30 to 36 weeks), and only one received palivizumab. The patient who received palivizumab had down syndrome, bronchopulmonary dysplasia, and cardiac disease (patient number 38 from figure 2).

Recurrent wheezing was not considered a comorbidity, and 8 patients in the 2019 cohort had experienced at least one previous wheezing episode. Among the 12 cases with rhinovirus co-infection, lower viral loads and shorter persistence of rhinovirus was observed compared to RSV values of the same patient. The Ct values for rhinovirus RNA detection ranged from 28 to 39.

### Viral Load Analysis

All patients had their first nasopharyngeal swab samples collected on the first or second day of hospitalization. Upon admission, the mean day of symptom onset was 5.11 ± 2.54, with a median of 5 (ranging from 4 to 6). Three caregivers reported symptoms lasting for more than 12 days at the time of admission.

The initial viral load in the first sample ranged from 4 to 8.01 log10 copies/ml, with a mean of 6.03 ± 1.10 and a median of 6.34 (ranging from 5.12 to 6.79). Peak viral load varied between 4.14 and 8.01 log10 copies/ml, with a mean of 6.3 ± 0.98 and a median of 6.49 (ranging from 5.67 to 6.92). In 40 patients (54.8%), the first viral load was identical to the peak viral load. The time to reach the peak viral load after the onset of symptoms is detailed in Table 2.

Individual viral load decay can be observed in Figures 1 to 4, while the distribution of viral loads for all patients based on the onset of symptoms is illustrated in Figure 5.

![Figure 1.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2024/08/31/2024.08.29.24312713/F1.medium.gif)

[Figure 1.](http://medrxiv.org/content/early/2024/08/31/2024.08.29.24312713/F1)

Figure 1. 
**RSV viral load decay, patients 1 to 21. Horizontal line corresponds to the cut of viral detection. Vertical lines indicate period of hospitalization.**

![Figure 2.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2024/08/31/2024.08.29.24312713/F2.medium.gif)

[Figure 2.](http://medrxiv.org/content/early/2024/08/31/2024.08.29.24312713/F2)

Figure 2. 
**RSV viral load decay, patients 22 to 39. Horizontal line correspond to the cut of viral detection. Vertical lines indicate period of hospitalization.**

![Figure 3.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2024/08/31/2024.08.29.24312713/F3.medium.gif)

[Figure 3.](http://medrxiv.org/content/early/2024/08/31/2024.08.29.24312713/F3)

Figure 3. 
**RSV viral load decay, patients 40 to 55. Horizontal line corresponds to the cut of viral detection. Vertical lines indicate period of hospitalization. Yellow strips correspond to intensive care unit period.**

![Figure 4.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2024/08/31/2024.08.29.24312713/F4.medium.gif)

[Figure 4.](http://medrxiv.org/content/early/2024/08/31/2024.08.29.24312713/F4)

Figure 4. 
**RSV viral load decay, patients 56 to 73. Horizontal line corresponds to the cut of viral detection. Vertical lines indicate period of hospitalization. Yellow strip correspond to intensive care unit period and red strip to invasive mechanical ventilation period.**

![Figure 5.](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2024/08/31/2024.08.29.24312713/F5.medium.gif)

[Figure 5.](http://medrxiv.org/content/early/2024/08/31/2024.08.29.24312713/F5)

Figure 5. 
**RSV viral load of samples from all patients according to symptom onset.**

The duration of viral shedding (viral persistence) was determined as the last day of RSV detection in relation to symptom onset. The mean viral persistence was 12.5 ± 5.72 days, with a median of 10 days (ranging from 9 to 15 days) and varying from 6 to 33 days. A total of 33 patients (45.2%) exhibited viral persistence exceeding the median of 10 days. To provide a more detailed perspective, viral persistence was further analyzed on a weekly basis, considering that samples were collected every 7 days, as displayed in Table 3.

No statistically significant associations were found between viral load markers (first viral load, peak viral load, and viral persistence) and the various covariates, including age, gender, RSV subgroup, comorbidities, rhinovirus co-detection, and recurrent wheezing. The complete linear regression analysis for the model A is shown on table 4.

### Analysis of severity outcomes

Frequency and length of studied outcomes are described on table 5. Severity outcomes were studied as dependent variables of the multiple linear regression. Possible variables of association were analyzed as covariates. Age was inversely correlated with higher hospitalization period (p=0.039), more days of oxygen use (p=0.039) and need for ICU (p=0.045). Patients who experienced viral persistence for more than 10 days were found to have a significant correlation with a longer hospitalization period (p=0.009), increased days of ventilation support (p=0.044), extended duration of IMV (p=0.035), prolonged requirement for nutritional support (p=0.038), and a longer course of antibiotic treatment (p=0.024). Mean and standard deviation of studied outcomes and p value for patients according to the 10-day RSV shedding are show on table 6. The complete linear regression analysis for model B is shown on table 7.

## Discussion

Our study presents the most extensive longitudinal examination of RSV viral load in AVB patients, with an analysis based on severity outcomes. Despite utilizing a convenience sample over a two-year period, we successfully detected RSV in 64% of AVB patients that were submitted to viral detection. The study spanned two years, with a gap between them due to the outbreak of the SARS-CoV-2 pandemic, which prompted isolation measures and the closure of schools. This was justified by the fact that several other studies reported a delayed RSV outbreak in the first year of SARS-CoV-2 pandemic22–24. A previous study from our group described the patients from the pre-pandemic period25. Nevertheless, our findings align with the rates reported in existing literature3,7. It’s worth noting that the pandemic’s impact was evident in the second year of the study, with the absence of children experiencing recurrent wheezing.

Upon hospital admission, the reported time since symptom onset averaged 5 days, aligning with the point in the disease course described in the literature when symptoms typically worsen7.

Our study revealed several findings that were consistent with existing literature. These included a majority of male patients, a higher incidence of the disease among younger patients (particularly those under 6 months of age), and a predominance of RSV subgroup A7,26–29. Notably, the proportion of severe outcomes in our study, such as the need for ICU admission (46.6%) and IMV (24.7%), was significantly higher than previously reported. This could be attributed to the exclusion of patients who were discharged from the hospital early and the specific characteristics of our hospital7,30.

### Viral load dynamics

Viral load and viral persistence have been the subject of investigation in several studies aiming to comprehend RSV viral decay. For instance, Takeyama et al. and Hall et al. collected daily RSV samples during hospitalization but did not continue to monitor patients after discharge9,31. Takeyama et al. reported similar findings, including the time to reach peak viral load and the absence of an association between viral load and RSV subgroup with disease severity.

In the study conducted by Brint et al.32, RSV samples were collected daily throughout the hospitalization period and for specific days following discharge, extending up to the 28th day, even when RSV was no longer detectable. In that study, 11.8% of patients exhibited RSV detection for over 1 month, which was a higher rate compared to our findings. The discrepancy in results, including a higher rate of viral load rebound (19.6%) compared to our study (12.3%), could potentially be attributed to variations in viral load measurement techniques and the systematic collection of samples even after RSV was no longer detectable. Viral load rebound was defined as a 10-fold increase in the viral load after a nadir, which happened after the 8th day of symptom onset, in two consecutive viral loads.

Viral load and viral persistence were not found to be associated with any of the patient characteristics (age, sex, comorbidities), RSV subgroup, or the presence of rhinovirus. This aligns with findings from other studies9,32,33.

### Severity Outcomes

Age was inversely associated with most severxity outcomes, as widely reported3,28. Our study could not find any association between quantitative viral load and severity outcomes. This association is controversial in the literature, with studies showing a positive association8,11, inverse association12,33 and others bringing no association at all34,35. Also, RSV subtype was not associated with severity outcomes; some studies corroborate this finding36,37, while others associate disease severity with the subgroup A38,39.

The primary and original data in our study was the association between viral persistence exceeding 10 days and most severity outcomes. The viral persistence may be a red flag for worsening outcomes and could encourage RSV detection and viral load quantification in patients with prolonged need for hospitalization and critical care. Future studies regarding treatment with antivirals and monoclonal antibodies could also address the benefit in RSV AVB patients with prolonged viral shedding.

Several limitations were experienced in our study. The accuracy of caregiver-provided information regarding the onset of symptoms, essential for standardizing the viral load curve, may be influenced by various factors, particularly prior upper airway infections, especially given the seasonal nature of respiratory viruses. There was an important loss of patients due to hospital transfer, as our hospital ward was not sufficient to hold all the patients during the peak of respiratory viruses’ seasonality. We also expected more patients with comorbidities, and for that reason we could not analyze them separately. Additionally, we did not explore the co-detection of other viruses and RSV genotypes, apart from the subgroup. It’s important to note that the severity of AVB can be influenced by a multitude of factors related to the virus, the patient, and external variables. Investigating all these factors simultaneously is a challenging in study design.

## Conclusion

Predictors of bronchiolitis severity can be highly complex. In addition to younger age, our study suggests that RSV viral persistence is associated to more severe disease. Further research into the dynamics of viral load in new studies may validate these findings. The information we have provided on viral shedding can contribute to a better understanding of RSV disease, particularly as several interventions, including vaccines, antivirals, and monoclonal antibodies, are anticipated to become available in the coming years.

## Supporting information

table 1 [[supplements/312713_file08.docx]](pending:yes)

table 2 [[supplements/312713_file09.docx]](pending:yes)

table 3 [[supplements/312713_file10.docx]](pending:yes)

table 4 [[supplements/312713_file11.docx]](pending:yes)

table 5 [[supplements/312713_file12.docx]](pending:yes)

table 6 [[supplements/312713_file13.docx]](pending:yes)

table 7 [[supplements/312713_file14.docx]](pending:yes)

## Data Availability

All data produced in the present study are available upon reasonable request to the authors

## Conflict of Interest Disclosures

The authors have no conflicts of interest to declare

## Abbreviations

ICU
:   Intensive care unit
IMV
:   Invasive mechanical ventilation
RSV
:   Respiratory syncytial virus
RT-qPCR
:   Reverse Transcription - quantitative Polymerase Chain Reaction
SARS-CoV-2
:   Severe acute respiratory syndrome coronavirus 2

## Contributors Statement Page

**Raí André Silva Watanabe:** data curation, formal analysis, investigation, project administration, visualization, writing - original draft.

**Luciano de Souza Luna:** investigation, methodology, validation.

**Danielle Dias Conte, Ana Helena Perosa:** investigation.

**Larissa Lyra, Filipe Nishiyama, and Bruno Sanchez Camargo:** investigation, formal analysis.

**Nancy Cristina Junqueira Bellei:** conceptualization, funding acquisition, supervision, writing - review and editing.

## Ethics statement

Ethics committee of UNIVERSIDADE FEDERAL DE SAO PAULO gave ethical approval for this work under N. 3.009.916 - CEP/UNIFESP n. 1082/2018. Consent was given from participants legal representatives to take part in the present study.

## Footnotes

*   Institutional mailing adresses: Raí André Silva Watanabe: rai.watanabe{at}unifesp.br, Filipe Nishiyama: filipe.nishiyama{at}unifesp.br, Larissa Lyra: larissa.lyra{at}unifesp.br, Bruno Sanchez Camargo: bruno.sanchez{at}unifesp.br, Danielle Dias Conte: dd.conte{at}unifesp.br, Nancy Cristina Junqueira Bellei: nbellei{at}unifesp.br

*   **Email adresses:** Raí André Silva Watanabe: raiandre{at}yahoo.com Filipe Nishiyama: filipe.nishiyama{at}gmail.com Larissa Lyra: larissalyra93{at}gmail.com, Bruno Sanchez Camargo: sanchez.bsc{at}gmail.com Luciano Kleber de Souza Luna: lksluna{at}gmail.com Danielle Dias Conte: daniellediasconte{at}gmail.com Ana Helena Perosa: anaperosa{at}gmail.com, Nancy Cristina Junqueira Bellei: nbellei{at}uol.com.br

*   Received August 29, 2024.
*   Revision received August 29, 2024.
*   Accepted August 31, 2024.


*   © 2024, Posted by Cold Spring Harbor Laboratory

The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.

## References

1.  1.Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986 Jun;140(6):543–6. doi: 10.1001/archpedi.1986.02140200053026. PMID: 3706232.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/archpedi.1986.02140200053026&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=3706232&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

2.  2.Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1. PMID: 20399493; PMCID: PMC2864404.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(10)60206-1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20399493&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000277655100027&link_type=ISI) 

3.  3.Meissner HC. Viral Bronchiolitis in Children. N Engl J Med. 2016 Jan 7;374(1):62–72. doi: 10.1056/NEJMra1413456.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMra1413456&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26735994&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

4.  4.Simões EAF. The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis. J Infect Dis. 2022 Aug 15;226(Suppl 2):S143–S147. doi: 10.1093/infdis/jiac211.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiac211&link_type=DOI) 

5.  5.Bénet T, Sánchez Picot V, Messaoudi M, et al. Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) Network; Global Approach to Biological Research, Infectious diseases and Epidemics in Low-income countries (GABRIEL) Network. Microorganisms Associated With Pneumonia in Children <5 Years of Age in Developing and Emerging Countries: The GABRIEL Pneumonia Multicenter, Prospective, Case-Control Study. Clin Infect Dis. 2017 Aug 15;65(4):604-612. doi: 10.1093/cid/cix378.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/cix378&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

6.  6.Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019 Aug 31;394(10200):757-779. doi: 10.1016/S0140-6736(19)30721-4. Epub 2019 Jun 27. Erratum in: Lancet. 2019 Aug 31;394(10200):736.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(19)30721-4&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

7.  7.Kyler KE, McCulloh RJ. Current Concepts in the Evaluation and Management of Bronchiolitis. Infect Dis Clin North Am. 2018 Mar;32(1):35–45. doi: 10.1016/j.idc.2017.10.002. Epub 2017 Dec 18.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.idc.2017.10.002&link_type=DOI) 

8.  8.El Saleeby CM, Bush AJ, Harrison LM, et al. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis. 2011 Oct 1;204(7):996–1002. doi: 10.1093/infdis/jir494.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jir494&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21881113&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

9.  9.Takeyama A, Hashimoto K, Sato M, et al. Respiratory syncytial virus shedding by children hospitalized with lower respiratory tract infection. J Med Virol. 2016 Jun;88(6):938–46. doi: 10.1002/jmv.24434. Epub 2015 Dec 1.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.24434&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=26588816&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

10. 10.Hijano DR, Brazelton de Cardenas J, Maron G, et al. Clinical correlation of influenza and respiratory syncytial virus load measured by digital PCR. PLoS One. 2019 Sep 3;14(9):e0220908. doi: 10.1371/journal.pone.0220908.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0220908&link_type=DOI) 

11. 11.Haddadin Z, Beveridge S, Fernandez K, et al. Respiratory Syncytial Virus Disease Severity in Young Children. Clin Infect Dis. 2021 Dec 6;73(11):e4384–e4391. doi: 10.1093/cid/ciaa1612.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/cid/ciaa1612&link_type=DOI) 

12. 12.Brenes-Chacon H, Garcia-Mauriño C, Moore-Clingenpeel M, et al. Age- dependent Interactions Among Clinical Characteristics, Viral Loads and Disease Severity in Young Children With Respiratory Syncytial Virus Infection. Pediatr Infect Dis J. 2021 Feb 1;40(2):116–122. doi: 10.1097/INF.0000000000002914.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/INF.0000000000002914&link_type=DOI) 

13. 13.Hartmann K, Liese JG, Kemmling D, et al. Clinical Burden of Respiratory Syncytial Virus in Hospitalized Children Aged ≤5 Years (INSPIRE Study). J Infect Dis. 2022 Aug 26;226(3):386–395. doi: 10.1093/infdis/jiac137.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiac137&link_type=DOI) 

14. 14.Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023 Jan;23(1):e2–e21. doi: 10.1016/S1473-3099(22)00291-2. Epub 2022 Aug 8.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(22)00291-2&link_type=DOI) 

15. 15.Ralston SL, Lieberthal AS, Meissner HC, et al. American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474–502. doi: 10.1542/peds.2014-2742. Erratum in: Pediatrics. 2015 Oct;136(4):782.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1542/peds.2014-2742&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=25349312&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000344385900029&link_type=ISI) 

16. 16.Fry AM, Chittaganpitch M, Baggett HC, et al. The burden of hospitalized lower respiratory tract infection due to respiratory syncytial virus in rural Thailand. PLoS One. 2010 Nov 30;5(11):e15098. doi: 10.1371/journal.pone.0015098.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0015098&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=21152047&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

17. 17.Emery SL, Erdman DD, Bowen MD, et al. Real-time reverse transcription- polymerase chain reaction assay for SARS-associated coronavirus. Emerg Infect Dis. 2004 Feb;10(2):311–6. doi: 10.3201/eid1002.030759.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3201/eid1002.030759&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15030703&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000188867700028&link_type=ISI) 

18. 18.Cruz JS, de Souza Luna LK, Alves VRG, et al. Viral load of respiratory syncytial virus among children from primary care and hospital settings admitted to a university hospital in Brazil (2009-2013). J Med Virol. 2021 Jun;93(6):3397–3400. doi: 10.1002/jmv.26185. Epub 2020 Sep 30.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.26185&link_type=DOI) 

19. 19.Fröhlich GC, Gregianini TS, Pinheiro FG, et al. LACEN-RS Team. Resurgence of human respiratory syncytial virus during COVID-19 pandemic in Southern Brazil. J Med Virol. 2024 Mar;96(3):e29551. doi: 10.1002/jmv.29551. PMID: 38506236.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/jmv.29551&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=38506236&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

20. 20.Shu B, Kirby MK, Davis WG, et al. Multiplex Real-Time Reverse Transcription PCR for Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2021;27(7):1821-1830. doi: 10.3201/eid2707.210462. PMID: 34152951; PMCID: PMC8237866.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3201/eid2707.210462&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34152951&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

21. 21.Gagliardi TB, Goldstein ME, Song D, et al. Rhinovirus C replication is associated with the endoplasmic reticulum and triggers cytopathic effects in an in vitro model of human airway epithelium. PLoS Pathog. 2022 Jan 7;18(1):e1010159. doi: 10.1371/journal.ppat.1010159. PMID: 34995322; PMCID: PMC8741012.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.ppat.1010159&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34995322&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

22. 22.Varela FH, Scotta MC, Polese-Bonatto M, et al. COVIDa study group. Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: Likely role of lower transmission in the community. J Glob Health. 2021 Mar 1;11:05007. doi: 10.7189/jogh.11.05007.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.7189/jogh.11.05007&link_type=DOI) 

23. 23.Eden, JS., Sikazwe, C., Xie, R. et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat Commun 13, 2884 (2022). doi:10.1038/s41467-022-30485-3
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/s41467-022-30485-3&link_type=DOI) 

24. 24.Garg I, Shekhar R, Sheikh AB, et al. Impact of COVID-19 on the Changing Patterns of Respiratory Syncytial Virus Infections. Infect Dis Rep. 2022 Jul 24;14(4):558–568. doi: 10.3390/idr14040059.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/idr14040059&link_type=DOI) 

25. 25.Watanabe RAS, Cruz JS, de Souza Luna LK, et al. Respiratory syncytial virus: viral load, viral decay, and disease progression in children with bronchiolitis. Braz J Microbiol. 2022 Sep;53(3):1241–1247. doi: 10.1007/s42770-022-00742-0. Epub 2022 Apr 1.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s42770-022-00742-0&link_type=DOI) 

26. 26.Calvo C, Pozo F, García-García ML, et al. Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatr. 2010 Jun;99(6):883–7. doi: 10.1111/j.1651-2227.2010.01714.x. Epub 2010 Feb 16.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1111/j.1651-2227.2010.01714.x&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=20163373&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000277320300020&link_type=ISI) 

27. 27.Mansbach JM, Piedra PA, Teach SJ, et al. MARC-30 Investigators. Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. Arch Pediatr Adolesc Med. 2012 Aug;166(8):700–6. doi: 10.1001/archpediatrics.2011.1669.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/archpediatrics.2011.1669&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22473882&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

28. 28.Espinosa Y, San Martín C, Torres AA, et al. Genomic Loads and Genotypes of Respiratory Syncytial Virus: Viral Factors during Lower Respiratory Tract Infection in Chilean Hospitalized Infants. Int J Mol Sci. 2017 Mar 21;18(3):654. doi: 10.3390/ijms18030654.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/ijms18030654&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28335547&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

29. 29.Rodriguez-Fernandez R, Tapia LI, Yang CF, et al. Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis. J Infect Dis. 2017 Dec 27;217(1):24–34. doi: 10.1093/infdis/jix543.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jix543&link_type=DOI) 

30. 30.Ghazaly M, Nadel S. Characteristics of children admitted to intensive care with acute bronchiolitis. Eur J Pediatr. 2018 Jun;177(6):913–920. doi: 10.1007/s00431-018-3138-6. Epub 2018 Apr 13.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s00431-018-3138-6&link_type=DOI) 

31. 31.Hall CB, Douglas RG Jr., Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr. 1976 Jul;89(1):11–5. doi: 10.1016/s0022-3476(76)80918-3.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0022-3476(76)80918-3&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=180274&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1976BW54000003&link_type=ISI) 

32. 32.Brint ME, Hughes JM, Shah A, et al. Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants. Pediatr Res. 2017 Nov;82(5):872–880. doi: 10.1038/pr.2017.173. Epub 2017 Aug 9.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1038/pr.2017.173&link_type=DOI) 

33. 33.Thwaites RS, Coates M, Ito K, et al. Reduced Nasal Viral Load and IFN Responses in Infants with Respiratory Syncytial Virus Bronchiolitis and Respiratory Failure. Am J Respir Crit Care Med. 2018 Oct 15;198(8):1074–1084. doi: 10.1164/rccm.201712-2567OC.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1164/rccm.201712-2567OC&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29688024&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

34. 34.Walsh EE, Wang L, Falsey AR, et al. Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection. J Infect Dis. 2018 Jun 20;218(2):208–217. doi: 10.1093/infdis/jiy106.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/infdis/jiy106&link_type=DOI) 

35. 35.Souza AP, Leitão LA, Luisi F, et al. Lack of association between viral load and severity of acute bronchiolitis in infants. J Bras Pneumol. 2016 Jul- Aug;42(4):261-265. doi: 10.1590/S1806-37562015000000241.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1590/S1806-37562015000000241&link_type=DOI) 

36. 36.Devincenzo, J. Natural Infection of Infants with Respiratory Syncytial Virus Subgroups A and B: A Study of Frequency, Disease Severity, and Viral Load. Pediatr Res 56, 914–917 (2004). doi:10.1203/01.PDR.0000145255.86117.6A
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1203/01.PDR.0000145255.86117.6A&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15470202&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 
    
    [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000225346700012&link_type=ISI) 

37. 37.Espinosa Y, San Martín C, Torres AA, et al. Genomic Loads and Genotypes of Respiratory Syncytial Virus: Viral Factors during Lower Respiratory Tract Infection in Chilean Hospitalized Infants. Int J Mol Sci. 2017 Mar 21;18(3):654. doi: 10.3390/ijms18030654.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/ijms18030654&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=28335547&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

38. 38.Jafri HS, Wu X, Makari D, Henrickson KJ. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr Infect Dis J. 2013 Apr;32(4):335–40. doi: 10.1097/INF.0b013e318282603a.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/INF.0b013e318282603a&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=23337904&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom) 

39. 39.Tabarani CM, Bonville CA, Suryadevara M, et al. Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection. Pediatr Infect Dis J. 2013 Dec;32(12):e437–42. doi: 10.1097/INF.0b013e3182a14407.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1097/INF.0b013e3182a14407&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2024%2F08%2F31%2F2024.08.29.24312713.atom)

 [1]: /embed/graphic-1.gif